Quantexa wraps up $175m Series F investment round
The round was led by Teachers' Venture Growth (TVG), part of the Ontario Teachers' Pension Plan.
Existing investors, including British Patient Capital, also participated in the round.
The latest funding round values the British technology company at $2.6bn.
Quantexa founder and CEO Vishal Marria said: "This latest investment reflects investors' embracing our vision and committing to join our journey as we accelerate innovation, platform deployments, and amplify the value we deliver to clients and the broader ecosystem.
'With the continued support of our investors, now including TVG, we are poised to push the boundaries of AI by harnessing the power of trusted data, reinforcing our leadership in this rapidly evolving landscape.'
The company said it plans to use the funds to accelerate platform innovation, enhance client experiences, and forge new partnerships and alliances.
The funding will also be used by the company to expand its presence in North America, and explore 'strategic' mergers and acquisitions.
As part of the investment, Ara Yeromian, managing director at TVG, will join Quantexa's board of directors, which also includes representatives from other investors such as Warburg Pincus, Dawn Capital, BNY, Evolution Equity Partners, AlbionVC, and HSBC.
Under the agreement, TVG will offer its expertise in scaling high-growth AI and software companies, along with its extensive network, to support Quantexa's international expansion and growth objectives.
TVG EMEA senior managing director and head Avid Larizadeh Duggan said: 'Businesses today need to build trusted data foundations to enable AI-enhanced decision making, to drive real world impact. Quantexa is revolutionising how they do this.
'At TVG, we invest in high-growth, game-changing companies, led by visionary leaders making a global difference. Quantexa's impressive track record, expanding customer base, and bold approach to data and AI innovation make it a natural fit for our portfolio.'
"Quantexa wraps up $175m Series F investment round" was originally created and published by Verdict, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
107% earnings growth over 1 year has not materialized into gains for Genuit Group (LON:GEN) shareholders over that period
Investors can approximate the average market return by buying an index fund. Active investors aim to buy stocks that vastly outperform the market - but in the process, they risk under-performance. For example, the Genuit Group plc (LON:GEN) share price is down 21% in the last year. That falls noticeably short of the market return of around 23%. At least the damage isn't so bad if you look at the last three years, since the stock is down 7.7% in that time. The falls have accelerated recently, with the share price down 13% in the last three months. This could be related to the recent financial results - you can catch up on the most recent data by reading our company report. If the past week is anything to go by, investor sentiment for Genuit Group isn't positive, so let's see if there's a mismatch between fundamentals and the share price. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price. During the unfortunate twelve months during which the Genuit Group share price fell, it actually saw its earnings per share (EPS) improve by 107%. It's quite possible that growth expectations may have been unreasonable in the past. The divergence between the EPS and the share price is quite notable, during the year. So it's easy to justify a look at some other metrics. Genuit Group's revenue is actually up 5.9% over the last year. Since the fundamental metrics don't readily explain the share price drop, there might be an opportunity if the market has overreacted. You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values). We know that Genuit Group has improved its bottom line lately, but what does the future have in store? This free report showing analyst forecasts should help you form a view on Genuit Group What About Dividends? As well as measuring the share price return, investors should also consider the total shareholder return (TSR). Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. We note that for Genuit Group the TSR over the last 1 year was -18%, which is better than the share price return mentioned above. This is largely a result of its dividend payments! A Different Perspective While the broader market gained around 23% in the last year, Genuit Group shareholders lost 18% (even including dividends). Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 0.6% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For instance, we've identified 1 warning sign for Genuit Group that you should be aware of. But note: Genuit Group may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on British exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 minutes ago
- Yahoo
Fletcher King Full Year 2025 Earnings: EPS: UK£1.48 (vs UK£0.028 in FY 2024)
Explore Fletcher King's Fair Values from the Community and select yours Fletcher King (LON:FLK) Full Year 2025 Results Key Financial Results Revenue: UK£3.84m (flat on FY 2024). Net income: UK£153.0k (down 46% from FY 2024). Profit margin: 4.0% (down from 7.4% in FY 2024). EPS: UK£1.48. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. All figures shown in the chart above are for the trailing 12 month (TTM) period Fletcher King shares are up 5.6% from a week ago. Risk Analysis We don't want to rain on the parade too much, but we did also find 3 warning signs for Fletcher King (1 is a bit unpleasant!) that you need to be mindful of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Los Angeles Times
21 minutes ago
- Los Angeles Times
Zero-G Biology
El Segundo-based Varda Space Industries is using space-based technology to manufacture complex pharmaceuticals in orbit, leveraging microgravity to create unique drug formulations for clients. — An El Segundo company has a novel solution to creating complex pharmaceuticals – using space tech to launch them into orbit The next frontier for medicine is closer to Los Angeles than San Francisco but feels like another galaxy. That's because it's about 300 miles straight up above sea level – in low-Earth orbit. Varda Space Industries, an El Segundo microgravity-enabled life sciences company, uses low-Earth orbit to develop unique drug formulations. It's a space-age approach to medicine that launches a capsule containing chemical compounds beyond Earth's atmosphere, where microgravity allows pharmaceutical formulations to be created in a process differently than on the surface. The capsules then reenter the atmosphere with their precious cargo. It became the first company to complete a manufacturing mission conducted outside of the International Space Station last year. Two more missions followed in early 2025 and a fourth launched on June 22. Varda plans to launch one more capsule this year and has four scheduled in 2026, which are all booked to capacity. 'What's special about next year is that the last two capsules will be going up on the same rocket. It will be the first time where we have two spacecraft in orbit at once, and we'll start to move into a fleet mentality,' said Will Bruey, chief executive and co-founder of Varda. Bruey, a former SpaceX engineer co-founded the company in 2021 with Delian Asparouhov, a former principal at Khosla Ventures. The company's growth is supported by a new round of investment. In July, the company announced a $187-million Series C round led by Natural Capital and Shrug Capital, with participation from Founders Fund, Peter Thiel, Khosla Ventures, Caffeinated Capital, Lux Capital and Also Capital. That brings total funding to $329 million. It will use the additional funds to scale operations so that it an expand its capsule production capacity, as well as open additional ground test facilities for pharmaceutical development. Additional capacity could eventually help lower costs – the average mission costs several million dollars today, although the finances are not measured by traditional revenue figures because there is potential to structure deals with royalties from the research and development conducted now. To support its additional manufacturing capabilities, it signed a 10,000-square-foot lease near its El Segundo headquarters for a dedicated lab space that will design molecules and test them prior to launch. The new laboratory will facilitate more complex experiments and allow it to research small molecules and move into more complex biologics. It currently has roughly 130 employees, and that number could increase to 180 within the next 12 months. Bruey envisions a time when there is a steady stream of capsules launching into, and returning from, space for biotech research, with launches on a weekly or daily basis. The company envisions scaling operations by launching more frequently, rather than trying to increase the size of their capsules to accommodate more experiments at a single launch. He likened it to his first job as a pizza delivery driver where the goal was to deliver many pizzas hot and fast to a large number of customers rather than waiting for a large order that required a semitruck to make the delivery. The capsules and satellite buses that carry them are constructed at the company's 61,000-square-foot headquarters where it forges raw materials into space vehicles. Those are then transported to Vandenberg Space Force Base up the coast near Santa Barbara for launch aboard a SpaceX rocket. Reusable rockets have lowered the cost of access to space and opened a range of in-space activities. Increased launch capabilities from companies, such as Long Beach-based Relativity Space, could lower costs even further as the lower-earth-orbit economy becomes more attainable as a destination for manufacturing, biotech, data centers and other technologies. Inside of the Varda capsule, custom-made lab equipment holds raw components that are mixed to form the targeted chemical compound. The device itself is small – measuring less than two feet tall by one foot wide. It has proprietary technology that is different from lab equipment on Earth. For example, a gas bubble that forms during an experiment on Earth would escape due to gravity, but it's not able to do so in space, so the equipment needs to account for environmental factors. Molecules could take a day or more to form, so the capsule remains in space for an extended period of time to complete the experiment. It also must preserve the temperature during re-entry and secure it from vibrations to ensure that the molecule is not destroyed. The capsule re-enters the atmosphere at speeds that reach Mach 25. Re-entry is supervised at the company's mission control center inside the headquarters building, where teams oversee both the capsule re-entry and its novel cargo. The capsule acts like a hypersonic wind tunnel at top speeds, so Varda has secured contracts with NASA and the Department of Defense to test materials for other applications beyond pharmeceutical development. This is also a third line of business – microgravity testing on materials for government and private clients – similar to the way that experiments are conducted on the International Space Station but with full automation and with the results delivered faster and at a lower cost than waiting for transportation to and from the space station. The typical Varda mission can last about two months. Varda is the first and only company to receive a special vehicle operator license under FAA Part 450. The W-4 mission is the first time the agency has issued that license, which allows it to reenter W-series capsules as needed without submitting new safety methodologies to the FAA for each identical flight. It has permission from the FAA to reenter capsules through 2029 before needing to renew the license. The W-4 mission is the maiden flight for Varda's next-generation spacecraft, which includes an in-house platform to navigate the spacecraft during the mission. While in orbit, the satellite bus provides the capsule with power, communications, attitude control and propulsion. When the capsule is ready for re-entry, it separates from the satellite bus and reenters, where it is recovered. Several startups have conducted test flights, such as German firm Atmos Space Cargo, California-based Outpost Space and Inversion Space, but none of these companies have successfully launched and landed a commercial mission. Meanwhile, SpaceX is reportedly interested in developing similar biotech capabilities to Varda. In some ways, the competition has helped Varda by lending validity to its approach to the larger biotech community, which is taking greater interest due to more capacity and competition. 'More people are getting to see the huge opportunity. We're actually pretty excited,' said Bruey. 'We've collaborated with SpaceX the last five years. Our partnership right now is focused on the launch aspect, and we'll continue to collaborate.' In February, Colorado-based Sierra Space, a commercial space and defense company that is building the Dream Chaser spaceplane, announced initiatives to advance research and development of biopharmaceutical solutions in low-Earth orbit during its inaugural mission to the International Space Station. Plans include conducting experiments to identify new ways to deliver cancer therapies to patients on Earth in collaboration with Merck. Another challenge for Varda is companies that are developing commercial space stations, such as Axiom Space, Blue Origin and Starlab Space. While these are in current development, they still have several years before they could come online. 'Once the commercial space stations have real estate in space, they will sell capacity or manufacturing,' said Dr. Leon Alkalai, chief executive at Mandala Space Ventures (and an investor in Varda). However, Varda has a real advantage built in to its ethos. 'Rather than thinking of manufacturing as a service, Varda is making it part of their core competency and betting on the value-add component to make themselves part of the value chain.' Overall, the space economy currently generates $613 billion in revenue, according to a recent report from The Space Foundation, which tracks revenue and spending on space technology. It projects that the space economy could grow to $1 trillion by 2032 at the current growth rate. Asparouhov credited an experiment published by pharmaceutical developer Merck in 2019 regarding the International Space Station as inspiration for Varda. That experiment demonstrated microgravity could develop higher-quality and more uniform crystallization. The applications could lead to new drug formations or entirely new medicines. For example, there is potential for medication that needs to be given intravenously to be recalibrated into a shelf-stable pill format. The company focus is both a biotech formulation platform and a space operation. It doesn't discover the molecules or choose what targets to go after. Rather, its business is to work within the pharmaceutical supply chain during the manufacturing process to open formulations that wouldn't otherwise exist. In a sense, the Varda system is a specialized piece of lab equipment that can introduce a new type of environment for biotech research. Bruey likened it to the introduction of other technologies such as cold and refrigeration, which have major implications on drug development. Crystallization and growth continue on Earth following the initial microgravity development. It's akin to a sourdough starter, which can be expanded to many loaves of bread once it's initially formed. Crystallization processes are commonly used in the manufacture of small molecules and small protein therapeutics. However, it has been challenging to identify the optimal crystallization processes for biologic drugs due to their large size and the flexibility of their structure. Once the drugs are developed, they are still required to go through testing, clinical trials and would need regulatory approval. A traditional drug development timeline could take a decade on average, and Bruey stated that he hopes that Varda's initial microgravity molecules could be available by the end of the decade for commercial use. 'The partners that we have see us as a pharmaceutical company. They don't see us as a space company. They bring us a drug that is having a particular problem, and we go solve it for them and hand it back,' said Asparouhov.
